Home Cart Sign in  
Chemical Structure| 1429054-28-3 Chemical Structure| 1429054-28-3

Structure of IDF-11774
CAS No.: 1429054-28-3

Chemical Structure| 1429054-28-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

IDF-11774 is a hypoxia-inducible factor (HIF)-1α inhibitor which regulates cancer metabolism, thereby suppressing tumor growth.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of IDF-11774

CAS No. :1429054-28-3
Formula : C23H32N2O2
M.W : 368.51
SMILES Code : CN1CCN(C(COC2=CC=C(C34CC5CC(C4)CC(C5)C3)C=C2)=O)CC1
MDL No. :MFCD31619285
InChI Key :QGBBBLPWBSWERZ-UHFFFAOYSA-N
Pubchem ID :71542096

Safety of IDF-11774

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of IDF-11774

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
WiDr cells 5 μM 72 hours To test the effect of SQLE knockdown on 5-FU sensitivity, results showed that SQLE knockdown increased the sensitivity of tumor cells to 5-FU treatment. PMC6265273
HCT116 cells 5 μM 72 hours To evaluate the effect of terbinafine on CRC cell viability, results showed that terbinafine significantly reduced the viability of HCT116 cells. PMC6265273
HCT116 human colon cancer cells 10 μM 12 hours IDF-11774 inhibited HIF-1α accumulation and reduced levels of glycolysis and TCA cycle intermediates, leading to an increased AMP/ATP ratio. PMC5520894
MC3T3-E1 cells 10 μM PS48 promoted the osteogenic ability of MC3T3-E1 cells, increasing the expression of PDK1 and osteogenic markers Runx2, OCN, and ALP. PMC9426532
B16F10 mouse melanoma cells 2.5 mM and 5.0 mM 48-72 hours IDF-11774 reduced HIF-1α protein expression, decreased cell survival, and increased cytotoxicity under CoCl2-induced hypoxic conditions. PMC9424330
MKN74 cells 15 µM and 30 µM 4 hours To evaluate the effect of IDF-11774 on HIF-1α expression, results showed that IDF-11774 significantly reduced HIF-1α expression PMC10748108
MKN45 cells 15 µM and 30 µM 4 hours To evaluate the effect of IDF-11774 on HIF-1α expression, results showed that IDF-11774 significantly reduced HIF-1α expression PMC10748108
K1 cells 15 μM and 30 μM 24 hours To evaluate the effect of IDF-11774 on the proliferation of K1 cells, results showed that IDF-11774 had no significant effect on the proliferation of K1 cells. PMC7558478
BCPAP cells 15 μM and 30 μM 24 hours To evaluate the effect of IDF-11774 on the proliferation of BCPAP cells, results showed that IDF-11774 inhibited the proliferation of BCPAP cells in a dose-dependent manner. PMC7558478
HT29 cells 5 μM 72 hours PMC6265273

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/c nude mice HCT116 human colon cancer xenograft model Oral administration 20 mg/kg/day Once daily for 15 days To evaluate the in vivo anti-tumor activity of IDF-11774, results showed that IDF-11774 significantly inhibited the growth of HCT116 xenograft tumors. PMC6265273
Balb/c nude mice HCT116 xenograft model Oral 50 mg/kg Once daily for 15 days IDF-11774 significantly suppressed tumor growth and showed anticancer efficacy in various cancer models. PMC5520894
Mice S. aureus infection-induced osteomyelitis model Oral 20 mg/kg/day Once daily for 7 days IDF-11774 treatment significantly reduced serum levels of IL-6, IL-1β, and CRP, as well as TGF-β1 concentration in infected mice. PMC9426532
Balb/c nude mice B16F10 melanoma transplantation model Oral 0, 10, 30, 60 mg/kg Once daily for 14 days IDF-11774 reduced tumor volume and local invasion, and downregulated HIF-1α expression. PMC9424330

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.57mL

2.71mL

1.36mL

27.14mL

5.43mL

2.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories